Ranbaxy Laboratories Ltd today announced the setting up of a second facility in Morocco, expanding its presence in the $1-billion Moroccan market and opening doors for direct business in North Africa.
Ranbaxy Morocco is now authorised to commence manufacturing at the new facility at Casablanca, Morocco, with the successful audit of the facility by the Moroccan health authorities, Ranbaxy said in a release.
"Ranbaxy has a significant presence in Africa with its own ground operations in key markets. Morocco is one of the important markets and this manufacturing facility further reinforces our commitment to the people of Morocco and the African continent," Mahendra Bhardwaj, head, Africa operations of Ranbaxy, said on the inauguration of the facility.
In addition to servicing the Morocco market, Ranbaxy also plans to extend the supply from this manufacturing unit to other African countries, in the coming years.
Ranbaxy already has a strong presence in Africa. Besides the two facilities in Morocco, the company has two other manufacturing units - one in Nigeria and the other in South Africa.
With five subsidiaries, five representative offices and a strong workforce of nearly 1,000 people, Ranbaxy's distribution network caters to 44 of the 54 countries in the African continent.
A subsidiary of the Daiichi Sankyo Group of Japan, Ranbaxy Laboratories Limited is also India's largest pharmaceutical company manufacturing and marketing a range of affordable generic and patented medicines worldwide.